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Background: The aim of this study was to investigate the incidence of benign histology 
after partial nephrectomy (PN) in patients with presumed malignancy from preoperative 
imaging. Further, preoperative predictors of benign lesions and perioperative outcomes 
were also assessed. 
 
Methods: A series of patients undergoing PN for renal masses was identified using a 
prospectively maintained database. Patients were excluded for known genetic 
conditions, if more than one renal mass was resected, or if standard preoperative 
imaging was not suspicious for RCC. Differences in characteristics between patients 
with benign and malignant pathology were assessed. 
 
Results: A total of 916 patients were identified that underwent PN between 2007-2015, 
including 129 (14.1%) patients with a final diagnosis of benign disease. The most 
common types of benign pathology were oncocytoma (n=66, 51.2%), angiomyolipoma 
(n=37, 28.7%), and complex cysts (n=10, 7.8%). Low BMI [0.96 (0.92-0.99) p=0.02], low 
R.E.N.A.L. score [0.86 (0.76-0.96) p=0.007], and low preoperative creatinine [0.37 
(0.14-0.91) p=0.04] predicted benign histology in multivariate analysis. Tumor size was 
a significant predictor in additional modeling [0.81 (0.69-0.94) p=0.008]. 
 
Patients with benign histology had significantly shorter operative times (p<0.001) and 
less estimated blood loss (p<0.001), and there was no difference in complication 
(p=0.93) or blood transfusion (0.24) rates. 












































































































































































































































































































































































































































Conclusions: In the current study, the rate of benign pathology after PN for presumed 
RCC is 14.1%. BMI, R.E.N.A.L. score, and preoperative creatinine are predictive of 
benign histology, but the ability of different variables to predict benign lesions may be 

































































































































































































































































































































































































































































Over 62,000 new cases of kidney cancer are expected in 2016, representing 
approximately 4% of all new diagnosed malignancies 1. Small, localized lesions 
represent the largest increase in renal cell carcinoma (RCC) incidence rate, and almost 
half of the new cases of RCC are localized tumors 2. It is thought that increased 
utilization of imaging modalities is responsible for the increased incidental finding of 
small renal masses 2. Multiple options with comparable oncological outcomes exist for 
management of these lesions, including both radical and partial nephrectomy (PN) 3, 
with PN being advantageous for most small lesions 4,5. As a result, both American and 
European guidelines recommend nephron-sparing surgery as standard of care for 
patients with T1 masses that can feasibly be resected 5. 
 
Improvements in preoperative imaging modalities have resulted in smaller lesions being 
detected, but these imaging techniques are often unable to distinguish benign lesions 
like oncocytoma or lipid-poor angiomyolipoma (AML) from RCC 6-8. As with any surgical 
procedure, there is potential morbidity associated with PN 3; in patients with lesions 
more likely to be benign, active surveillance may be more appropriate than PN. Few 
studies have investigated the incidence of benign lesions after PN 7,9-15. Reported rates 
have been between 8.1%-32.6%, but the number of patients in many of these series is 
limited. Selected studies with >100 patients are summarized in Supplemental Table 1. 
There are few contemporary studies that investigate the benign pathology rate in larger 











































































































































































































































































































































































































































series of all patients undergoing PN for renal masses presumed to be RCC. Therefore, 
the purpose of this study was to investigate the incidence of benign renal lesions after 
PN in a single-center series of patients with presumed malignancy from preoperative 
imaging. Further, this study aims to investigate perioperative outcomes of patients 




After approval by the Washington University Institutional Review Board, all patients 
undergoing partial nephrectomy between 2007 and 2015 were retrospectively identified 
using a consented, de-identified, prospectively maintained database. All patients were 
included in this study if pre-operative imaging was suspicious for malignancy, which was 
defined as solid enhancing masses or complicated renal cysts classified as Bosniak 
category III or IV 16. For inclusion criteria for this study, all surgical events logged as 
“partial nephrectomy” were identified. Patient exclusion criteria included the following: 
von Hippel-Landau syndrome, tuberous sclerosis, Birt-Hogg-Dubé syndrome, resection 
of more than one renal mass, and preoperative imaging consistent with benign lesions 
(e.g. lipid-rich AML, excluded calyx). The final cohort of patients underwent a single PN 















































































































































































































































































































































































































































Surgical approach was chosen based on history of abdominal surgery, patient habitus, 
tumor location, and surgeon and patient preference. Laparoscopic operations were 
performed using a transperitoneal or retroperitoneal approach with clamping of the renal 
vessels 17. Open PN was chosen primarily for large, endophytic tumors, and was based 
on surgeon preference. Robotic-assisted partial nephrectomy (RAPN) operations were 
performed with a retroperitoneal or transperitoneal approach, as described previously 18. 
Off-clamp technique was chosen based on tumor location, patient characteristics, and 
surgeon preference 19. 
 
Biopsy Procedure and Specimen Evaluation 
 
All biopsies were performed preoperatively in order to help better inform management 
decisions. Patients receiving anti-coagulants were instructed to discontinue their 
medication for an amount of time appropriate for the diminution of its effects prior to 
biopsy. Biopsies were performed by experienced abdominal radiologists and 
interventional radiologists. Ultrasound (US) guidance is preferred at our institution and 
was used for all masses that were detectable sonographically. Computed tomography 
(CT) guidance was reserved for masses not well-demonstrated by US. The number of 
biopsy cores taken was at the discretion of the radiologist. Immediate post-biopsy 
















































































































































































































































































































































































































































Staff data managers and physicians prospectively collected patient demographics, 
perioperative outcomes, and tumor characteristics. Preoperative CT or magnetic 
resonance imaging (MRI) was interpreted by fellowship-trained genitourinary 
radiologists before the time of surgery, and genitourinary pathologists were responsible 
for making the final diagnosis. Perioperative complications were defined using the 
Clavien grading system 20, and major complications were defined as Clavien grade III or 
IV. Renal biopsy data was queried using a prospectively maintained database, and all 




To analyze the association of preoperative variables with benign histology, chi-square 
analysis, Fisher’s exact test, or Mann-Whitney U test were used. Multivariable modeling 
of predictors of benign histology was performed using logistic regression with the 
following variables: gender, age, nephrometry score, body mass index, and 
preoperative creatinine. Tumor size was not included in this multivariate model due to 
collinearity with the “R” term of R.E.N.A.L. However, a separate model was constructed 
which included all of the original covariates but included tumor size and excluded 
R.E.N.A.L. Differences in perioperative outcomes between benign and malignant 
tumors were assessed using chi-square analysis, Fisher’s exact test, or Mann-Whitney 
U. All analysis was performed using R software (v3.1.3), and a two-tailed p-value <0.05 
was considered significant in all analyses. 














































































































































































































































































































































































































































A total of 916 patients were identified that underwent partial nephrectomy at our 
institution from 2007-2015, including 59 patients with open procedures, 96 patients with 
laparoscopic operations, and 754 patients undergoing RAPN. Seven patients were 
classified as having open procedures after conversion from laparoscopic or robotic-
assisted operations. The mean BMI of this patient cohort was 31.1, and the mean age 
was 57.5 years. Baseline patient demographics are further described in Table 1. 
 
Of the 916 patients in this study, 129 (14.1%) patients revealed benign pathology upon 
final diagnosis (Table 1), including 66 (51.2%) patients with oncocytoma, 37 (28.7%) 
with angiomyolipoma (AML), 10 (7.8%) with complicated cysts, and 16 (12.4%) with 
miscellaneous other benign pathology. Other benign pathology included metanephric 
adenoma (4), simple cyst (3), heterotopic adrenal cortex (2), Castleman’s disease (1), 
hemangioma (1), organizing hematoma (1), schwanomma (1), obstructive nephropathy 
(1), pseudocyst (1), and leimyoma (1). The rate of benign histology after PN specifically 
for masses ≤4 cm was 15.1%. 
 
From 2007-2015, a total of 92 biopsies were performed of unilateral renal masses ≤10 
cm, including 35 biopsies in masses ≤4 cm. Of the 92 patients undergoing biopsy, 10 
(10.9%) patients had benign pathology upon biopsy. One patient with benign biopsy 











































































































































































































































































































































































































































histology underwent partial nephrectomy, and operative histology confirmed benignity. 
The remaining 9 patients were managed conservatively. 
 
The association of different preoperative variables with benign histology after surgery 
was then assessed in univariate analysis (Table 2). Compared to patients with a final 
diagnosis of malignancy, patients with benign histology had significantly lower BMIs 
(p=0.003), lower nephrometry scores (p=0.01), fewer comorbidities (p=0.04), smaller 
tumor sizes (p<0.001), and lower preoperative creatinine (p=0.04). Within the 
R.E.N.A.L. nephrometry scoring system, exophyticity (p<0.001) and a greater distance 
from the collecting system (p=0.005) were associated with benign pathology, while 
anterior/posterior location (p=0.31) and tumor relation to polar lines (p=0.14) were not 
associated. No difference was found between patients with benign and malignant 
tumors for the following variables: age at surgery, history of diabetes or hypertension, 
preoperative hemoglobin, and tumor laterality (p>0.05 for all). Female gender 
approached significance for benign pathology (p=0.053).  
 
A multivariable model was constructed to investigate the independent predictive ability 
of each variable (Table 3). Low body mass index [0.96 (0.92-0.99) p=0.02], low 
R.E.N.A.L. score [0.86 (0.76-0.96) p=0.007], and low preoperative creatinine [0.37 
(0.14-0.91) p=0.04] were independently predictive of benign histology after PN. In the 
second multivariate model including tumor size and not R.E.N.A.L., tumor size was a 
significant predictor of benign histology [0.81 (0.69-0.94) p=0.008]. 
 











































































































































































































































































































































































































































Perioperative outcomes between patients with benign vs. malignant histology after PN 
were then evaluated (Table 4). A total of 17 (13.4%) patients with benign histology had 
perioperative complications, including 6 (4.7%) patients with Clavien grade III or IV 
complications (Supplemental Table 2). There was no difference in the rate of 
complications between patients with benign and malignant pathology (p=0.93). 
Similarly, both set of patients received perioperative blood transfusions at similar rates 
(p=0.24). Patients with benign histology had significantly shorter operative times 




PN is the gold standard for management of renal masses ≤4 cm in healthy patients, and 
this is reflected in both American and European guidelines 5. Renal masses are often 
found incidentally via imaging modalities 2, and previous groups have reported rates of 
benign histology after PN for these masses upwards of 30% 14. Because most previous 
studies are limited by low patient numbers, the aim of this study was to investigate the 
rate of PN is a large series of PN patients over the span of 8 years. In this study, we 
found an incidence of benign lesions of 14.1% in patients undergoing PN for a solitary 
renal lesion, and an incidence of 15.1% in renal masses ≤4 cm. 
 
 The rates of benignity vary across studies, though the results herein are similar to 
those in most other large-scale reports. In two different series of Japanese patients, 
pathologic reports revealed benign findings after PN in 8.1% and 11% of patients 7,15. A 











































































































































































































































































































































































































































2004 report by Marszalek et al. found a benign rate of 32.6% in 129 patients. In 2006, a 
study of 143 patients with presumed malignant renal masses from preoperative imaging 
found that 16.1% of patients had benign histology 10. In two recent studies, benign rates 
of 20-22% were found in lesions ≤4 cm 9,11. Multicenter results on 873 patients from 
Mullins et al. are similar with a benign rate of 23.1% for all patients undergoing RAPN 21. 
The present study is the largest series of patients to date to investigate the rate of 
benign histology after PN for patients specifically with presumed malignancy based on 
preoperative imaging, rather than the benign rate in all PN patients 21. 
 
Despite advancements in radiologic protocols, distinguishing benign lesions with CT or 
MRI imaging is difficult, and previous studies have investigated whether other 
preoperative, clinical characteristics can predict benign histology after PN 9,15. In 2010, 
Jeon et al. reported that female gender, age at surgery, and year of surgery were 
independently predictive of benign lesions 9. Fujita et al. found similar results in 2014, 
with age, gender, and exophytic properties as significantly predictive 15. Gender was 
also significant in a recent paper by Mullins et al., along with tumor complexity 21. 
Interestingly, in the cohort of patients included in the present study, neither gender nor 
age was significantly associated with benign histology. R.E.N.A.L. score, tumor size, 
preoperative creatinine, and body mass index were the only characteristics 
independently associated with final histologic diagnosis in this study.  
 
Because the clinical associations with benignity in our study differ from previous studies 
9,15, we hypothesized that the reason for discrepancy was based upon the distribution of 











































































































































































































































































































































































































































benign lesion types between the studies. Indeed, 28.6% of benign masses in our cohort 
were classified as AML and 49.2% of lesions were oncocytoma, while Jeon et al. had a 
distribution of 43.2% AML and 13.6% oncocytoma 9, leading to a statistically significant 
difference in the distribution of benign lesions in our study vs. Jeon et al. (p<0.0001; 
data not shown). Given the known association of AML with middle-aged females 22, it is 
not surprising that age and gender predict benign pathology in a cohort of patients with 
high representation of AML.  
 
Mullins et al. evaluated a multicenter series of 873 RAPNs 21. The authors found a rate 
of benign lesions of 23.1% and that male gender and tumor complexity by RNS 
predicted malignancy.  Although there are similarities in the described cohorts, our 
present work represents the findings of all patients undergoing any approach to PN at a 
single-institution, as opposed to those undergoing specifically RAPN. Moreover, the 
distribution of benign histology subtypes again differs.  For example, the rate of benign 
cysts in the series by Mullins et al. was 15.8% of benign lesions, compared to 10.1% in 
the present study; AML was also represented at a higher rate in the report by Mullins et 
al. than our study (p=0.053; data not shown). The results of our single-center 
experience highlight differences in tumor histology subtypes that may reflect improved 
detection of lipid-poor AML by radiology and urology staff, leading to fewer surgeries for 
these patients, and a greater representation of oncocytoma in our cohort. 
 
The differences in the series presented by Jeon et al, Mullins et al., and our present 
work suggest that models to predict benign histology may be biased by the distribution 











































































































































































































































































































































































































































of benign lesion subtypes within a population. It is therefore likely a result of an 
unrecognized selection bias. Strong collaboration with radiology may lead to better 
identification of certain types of benign lesions such as lipid-poor AML, thus skewing the 
final distribution of patients undergoing surgery. This presents a potential confounding 
bias in analysis that has previously been unidentified. 
 
Surgery carries both inherent risk and significant cost, and reducing the number of 
operations for benign histology may diminish financial burden and the number of 
patients with complications of surgery. In this study, we investigated perioperative 
outcomes of patients undergoing PN for benign and malignant lesions. While operative 
times and blood loss were lower in patients with benign histology, there were similar 
rates of transfusions and complications between the groups. In particular, 17 (13.2%) 
patients with benign histology had perioperative complications, including six (4.7%) 
patients with Clavien grade 3 or 4 complications. The rate of complications for patients 
with benign lesions in this study is consistent with previous reports and similar to the 
complication rate for malignant lesions in our population.  
 
The use of imaging and clinically based predictive models for benign histology has the 
potential to spare some patients from unnecessary operations and resultant 
complications. There is also provocative evidence that supports routine renal mass 
biopsies in patients with suspicious masses 23,24. In patients with equivocal clinical and 
radiographic findings, renal biopsy may help distinguish benign from malignant 
histology. Previous authors have pronounced the utility of biopsy in guiding risk 











































































































































































































































































































































































































































stratification and management decisions, in many cases toward the avoidance of 
potentially unnecessary surgery (for benign tumors or indolent cancers) 24,25. Osawa et 
al. reported on a series of 202 biopsied small renal masses. The authors described the 
assignment of 53 (26%) of those tumors to active surveillance rather than surgery, 
although 9/53 (17%) were ultimately determined to have been improperly assigned 
based on less favorable final pathology 26. Furthermore, Halverson et al. found a 
concordance rate between biopsy and final pathology of 92% in a series of 151 tumors 
24. In addition to biopsy, other biomarkers have been shown to effectively discriminate 
between RCC (clear and papillary subtypes) and benign lesions, such as urinary 
biomarkers aquaporin 1 and perilipin 2 27. Ultimately, better prognostic models will need 
to be disease-specific (e.g. AML and oncocytoma) and potentially include a combination 
of clinical and radiographic parameters, as well as urinary biomarkers and biopsy 
pathology. Such models may help reduce the number of patients undergoing 
unnecessary PN for benign lesions. 
 
Potential selection bias is a limitation of this study due to the retrospective design. The 
indications for elective PN at our institution are similar to the indications reported by 
other institutions. However, it is possible that patients with small renal masses, elevated 
creatinine, and higher BMIs were considered more preferentially for preoperative 
biopsy, active surveillance, or image-guided ablation. Renal biopsy can influence 
management decisions, and in our practice, only 10% of patients with a benign biopsy 
underwent partial nephrectomy. However, given the overall low number of patients 
biopsied relative to the total number of partial nephrectomies performed, it is unlikely 











































































































































































































































































































































































































































that renal biopsy pathology significantly affected the results and conclusions herein. 
Patient preferences and perceptions regarding the characterization and treatment of 
their renal mass also add to the selection bias in this population. Our dataset does not 




The rate of benign pathology after PN for presumed RCC is 14.1% in all patients and 
15.1% in patients with renal masses ≤4 cm. Patients with benign lesions have favorable 
perioperative outcomes for blood loss and operative time. Body mass index, R.E.N.A.L. 
score, and preoperative creatinine are predictive of benign histology, potentially 
reflecting an undetected selection bias. However, the ability of different variables to 
predict benign lesions may be influenced by the distribution of benign tumor subtypes. 
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RCC = renal cell carcinoma 
PN = partial nephrectomy 
AML = angiomyolipoma 
RAPN = robotic-assisted partial nephrectomy 
CT = computed tomography 
MRI = magnetic resonance imaging 
BMI = body mass index 
US = ultrasound 
 
  











































































































































































































































































































































































































































Table 1: Demographics of patients undergoing partial nephrectomy for presumed RCC 
 
Characteristic N (%) 
Type of partial nephrectomy  
       Open 59 (6.4%) 
       Laparoscopic 96 (10.5%) 
       RAPN 754 (82.3%) 
       Laparoscopic converted to open 1 (0.1%) 
       RAPN converted to open 6 (0.7%) 
History of diabetes  
       No 634 (76.7%) 
       Yes 193 (23.3%) 
       Unavailable 89 
History of hypertension  
       No 305 (36.9%) 
       Yes 522 (63.1%) 
       Unavailable 89 
Tumor laterality  
       Left 439 (47.9%) 
       Right 477 (52.1%) 
Perioperative complications  
       No complications 728 (86.9%) 
       Complications 110 (13.1%) 
       Unavailable 78 
Perioperative blood transfusion  
       No transfusion 799 (95.0%) 
       Perioperative transfusion 42 (5.0%) 
       Unavailable 75 
Charlson Comorbidity Index  
       0 414 (50.1%) 
       1 177 (21.4%) 
       2 113 (13.7%) 
       ≥3 123 (14.9%) 
       Unavailable 89 
Tumor histology  
       Benign 129 (14.1%) 
       Malignant 787 (85.9%) 
Histology in tumors ≤4cm  
       Benign 110 (15.1%) 
       Malignant 620 (84.9%) 
Age at surgery (years), mean (±SD) (n=916) 57.5 (±12.1) 
Body mass index, mean (±SD) (n=882) 31.1 (±7.1) 
R.E.N.A.L. score, mean (±SD) (n=678) 7.6 (±1.9) 
Radiographic tumor size (cm), n, mean (±SD) 911, 3.1 (±1.6) 
Preoperative hemoglobin (g/dL), n, mean (±SD) 776, 13.8 (1.6) 
Preoperative creatinine (mg/dL), n, mean (±SD) 833, 0.94 (0.35) 
 
Abbreviations: renal cell carcinoma (RCC), robot-assisted partial nephrectomy (RAPN) 
 
 























































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2: Univariable analysis of preoperative predictors of benign kidney histology 
 
Characteristic Benign (n=129) Malignant (n=787) p-value 
Age at surgery (years), mean (±SD) 59.0 (±11.8) 57.3 (±12.2) 0.15 
Body mass index, mean (±SD) 29.4 (±5.6) 31.4 (±7.3) 0.003 
Gender, n (%)   0.053 
       Female 66 (51.2) 331 (42.1)  
       Male 63 (48.8) 456 (57.9)  
History of diabetes, n (%)   0.07 
       No 107 (82.9) 527 (75.5)  
       Yes 22 (17.1) 171 (24.5)  
       Missing data 0 89  
History of hypertension, n (%)   0.90 
       No 47 (36.4) 259 (37.0)  
       Yes 82 (63.6) 440 (63.0)  
       Missing data 0 88  
Charlson comorbidity index, n (%)   0.04 
       0 76 (58.9) 338 (48.4)  
       1 28 (21.7) 149 (21.3)  
       2 15 (11.6) 98 (14.0)  
       >=3 10 (7.8) 113 (16.2)  
       Missing data 0 89  
R.E.N.A.L. score, mean (±SD) 7.1 (±2.0) 7.7 (±1.8) 0.01 
Radiographic tumor size (cm), mean (±SD) 2.7 (±1.5) 3.2 (±1.6) <0.001 
Tumor location relative to polar lines, n (%)   0.14 
       Entirely above/below 40 (40.0) 163 (30.0)  
       Crosses polar lines 30 (30.0) 188 (34.6)  
       >50% over polar lines 30 (30.0) 193 (35.5)  
       Missing data 29 243  
Nearness to collecting system, n (%)    
       >=7 30 (30.0) 103 (18.9) 0.005 
       4-7 23 (23.0) 92 (16.9)  
       <=4 47 (47.0) 349 (64.2)  
       Missing data 29 243  
Exophyticity, n (%)   <0.001 
       >=50% 45 (45.0) 141 (25.9)  
       <50% 35 (35.0) 312 (57.4)  
       Endophytic 20 (20.0) 91 (16.7)  
       Missing data 29 243  
Anterior/posterior location, n (%)   0.31 
       Anterior 46 (40.4) 205 (33.6)  
       Posterior 33 (28.9) 214 (35.1)  
       Neither 35 (30.7) 191 (31.3)  
       Missing data 15 177  
Tumor laterality, n (%)   0.82 
       Left 63 (48.8) 376 (47.8)  
       Right 66 (51.2) 411 (52.2)  
Preoperative creatinine (mg/dL), mean (±SD) 0.88 (±0.30) 0.96 (±0.37) 0.04 
Preoperative hemoglobin (g/dL), mean (±SD) 13.6 (±1.5) 13.9 (±1.6) 0.10 
 























































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3: Multivariable analysis of preoperative predictors of benign kidney histology 
 
Characteristic Odds ratio [95% CI] p-value 
Gender (ref=female) 0.98 [0.61-1.56] 0.92 
Age at surgery (per yr.) 1.02 [1.00-1.04] 0.08 
R.E.N.A.L. score (per unit) 0.86 [0.76-0.96] 0.007 
Body mass index (per unit) 0.96 [0.92-0.99] 0.02 

















































































































































































































































































































































































































































Table 4: Perioperative outcomes of patients with benign and malignant kidney histology 
after PN 
 
Characteristic Benign Malignant p-value 
Perioperative complications, n (%)   0.93 
       No complications 110 (86.6) 618 (86.9)  
       Complications 17 (13.4) 93 (13.1)  
       Missing data 2 76  
Blood transfusion rate, n (%)   0.24 
       No perioperative BT 118 (92.9) 681 (95.4)  
       Perioperative BT 9 (7.1) 33 (4.6)  
       Missing data 0 75  
Operative time (min), mean (±SD) 146.9 (±51.8) 165.6 (±54.5) <0.001 
Estimated blood loss (ml), mean (±SD) 158 (±233) 223 (±284) <0.001 
 



















































































































































































































































































































































































































































Supplemental Table 1: Reports rates of benign lesions in recent large series of patients 







AML  Oncocytoma  Cyst Other 
  N n, % total n, % 
total 
n, % total n, % total n, % 
total 
Fujii et al.  200
8 
176 19 (11%) 10 (5.7%) 5 (2.8%) 2 (1.1%) 1 (0.6%) 
Jeon et al. 201
0 
376 81 (21.5%) 35 (9.3%) 11 (2.9%) 26 (6.9%) 9 (2.4%) 
Kutikov et al. 200
6 
143 23 (16.1%) 10 (7.0%) 8 (5.6%) 3 (2.1%) 1 (0.7%) 
Pederson et al. 201
4 
151 23 (15.2%) 7 (4.6%) 12 (7.9%) NR 4 (2.6%) 
McKiernan et al. 200
2 
291 64 (22.0%) 12 (4.1%) 31 (10.7%) 14 (4.8%) 7 (2.4%) 
Pahernik et al.  200
6 
504 123 (24.4%) 33 (6.5%) 53 (10.5%) 23 (4.6%) 13 
(2.8%) 
Marszalek et al. 200
4 
129 42 (32.6%) 7 (5.5%) 10 (7.8%) 18 (13.9%) 
 
7 (5.4%) 
Fujita et al. 201
4 
149 12 (8.1%) 5 (3.4%) 5 (3.4%) 0 (0%) 2 (1.3%) 















































































































































































































































































































































































































































Supplemental Table 2: Postoperative complications of patients undergoing partial 
nephrectomy with a final diagnosis of benign pathology 
 
Clavien Grade n (%) Complications 
Clavien I 3 (17.6) fever (1), urinary retention (2) 
Clavien II 7 (41.2) 
blood transfusion (2), hypertensive crisis 
(1), deep vein thrombosis (1), fever (1), 
atrial fibrillation (1), pulmonary embolism 
(1), shortness of breath (1) 
Clavien III 6 (35.3) 
pseudoaneurysm (5), reintubation due to 
hypoxia (1), acute kidney failure (1) 
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